PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Gross profit growth of 12.50% while AVXL is zero. Bruce Berkowitz would see if minimal improvements could expand further.
-29.39%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-29.39%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-30.95%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-22.58%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-22.58%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
7.95%
Share count expansion well above AVXL's 0.47%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.95%
Diluted share count expanding well above AVXL's 0.47%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-8.11%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-7.95%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AVXL stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.14%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
75.06%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
-16.88%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-109.23%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
62.10%
5Y net income/share CAGR above 1.5x AVXL's 24.73%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-51.96%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-71.08%
Negative equity/share CAGR over 10 years while AVXL stands at 84.65%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-53.15%
Negative 5Y equity/share growth while AVXL is at 444.97%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-63.40%
Negative 3Y equity/share growth while AVXL is at 48.34%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Positive asset growth while AVXL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-7.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-6.71%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
37.48%
R&D growth drastically higher vs. AVXL's 12.03%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
21.30%
SG&A growth well above AVXL's 6.94%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.